BIOTECH ASSISTANT / FIELD NOTES

C4 completes first cemsidomide–elranatamab safety-cohort enrollment and updates Phase 2 timeline

Company / institutional announcement · C4 Therapeutics (GlobeNewswire)

Source published: 2026-11-05

Site published: 2026-11-07 · Updated: 2026-11-07

Explore this article with AI

This source is linked automatically. Choose a question to get started.

Ask AI ↗

Findings and limitations Industry implications Related developments

What changed

C4 Therapeutics reported completed enrollment of the first safety cohort in its Phase 1b cemsidomide–elranatamab combination trial. It expects Phase 2 MOMENTUM enrollment to finish in the first quarter of 2027, with initial response-rate data in the second half. At September 30, cash, cash equivalents and marketable securities totaled $274.7 million, with projected runway through 2028.

Why it may matter

Potential business implication: combination-cohort progress clarifies near-term degrader development milestones, while projected cash runway and response-readout timing remain company expectations.

The interpretation above is analysis, not a conclusion attributed to the original source.

Read the original source ↗

Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections

Protein degradation / PROTAC

Follow the evidence

Companies mentionedC4 Therapeutics ↗

Explore field companies →Explore literature →

Related updates

2026-11-06Nature Materials

In situ CAR engineering and nanoparticle-mediated TREM2 degradation for macrophage reprogramming in malignant ascites

A Nature Materials study describes mRNA-loaded LNPs that reprogram tumor-associated macrophages into Claudin18.2-targeting CAR macrophages. The lipid formulation also promotes TREM2 internalization and degradation, reshaping immune responses. The original abstract reports tumor suppression and longer survival with PD-1 blockade in mice, plus ex vivo patient-sample findings. These findings do not demonstrate clinical efficacy in treated patients.

mRNA / LNP In Vivo Cell Engineering & Gene Editing Protein degradation / PROTAC Ask AI ↗

2026-11-06Frontiers in Pharmacology

Review assesses the safety limits and translational gaps of MCL-1 degradation strategies

A Frontiers in Pharmacology review compares direct MCL-1 inhibition with approaches that reduce its abundance, including transcriptional interventions and targeted degradation. The original abstract highlights limited single-agent activity and cardiac safety concerns with inhibitors, while positioning degradation as an unvalidated clinical strategy. Biomarker-guided combinations and dynamic BH3 profiling are discussed; this review does not report a new clinical trial.

Protein degradation / PROTAC Ask AI ↗

2026-11-05Evommune and Hinova / Business Wire

Evommune licenses Hinova's VAV1 molecular glue degrader outside Greater China

Evommune licensed EVO570, formerly HC118, from Hinova for development and commercialization outside Greater China. Upfront consideration totals $30 million: $20 million cash and $10 million in pre-funded warrants. Additional development, regulatory, and commercial milestones could reach approximately $1.1 billion, plus royalties. Phase 1 was expected to begin shortly; the announcement does not establish human efficacy.

Protein degradation / PROTAC Ask AI ↗

Continue your research

All company profiles, filters, and comparisons are open. Sign in for private saves and member discussions.

Open full company map ↗